Genprex, Inc. (GNPX)
Stock Price:
$3.15 USD
-0.03 (-0.94%)
Updated Jul 9, 2020 8:39 AM EDT - Market open
Key Info
| Market Cap |
121.68M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-14.06M |
| Shares Out |
38.63M |
| EPS (ttm) |
-0.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 9, 2020 |
| Last Price |
$3.15 |
| Previous Close |
$3.18 |
| Change ($) |
-0.03 |
| Change (%) |
-0.94% |
| Day's Open |
3.18 |
| Day's Range |
3.07 - 3.32 |
| Day's Volume |
49,132 |
| 52-Week Range |
0.23 - 7.03 |
More Stats
| Market Cap |
121.68M |
| Enterprise Value |
98.60M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.63M |
| Float |
26.78M |
| EPS (basic) |
-0.72 |
| EPS (diluted) |
-0.73 |
| FCF / Share |
-0.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.25M |
| Short Ratio |
1.85 |
| Short % of Float |
9.52% |
| Beta |
-1.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.08 |
| Revenue |
n/a |
| Operating Income |
-14.09M |
| Net Income |
-14.06M |
| Free Cash Flow |
-10.72M |
| Net Cash |
23.08M |
| Net Cash / Share |
0.60 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-54.83% |
| ROE |
-90.18% |
| ROIC |
-3,085.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.50*
(106.35% upside)
Low
5.00
Current: 3.15
High
8.00
Target: 6.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -10.68 | -12.36 | -3.31 | -4.13 | -1.07 |
| Net Income | -10.65 | -12.37 | -3.31 | -4.13 | -1.07 |
| Shares Outstanding | 16.03 | 13.77 | 11.50 | 10.83 | 1.87 |
| Earnings Per Share | -0.66 | -0.90 | -0.29 | -0.38 | -0.57 |
| Operating Cash Flow | -6.92 | -6.85 | -2.17 | -1.25 | -0.69 |
| Capital Expenditures | -0.84 | -0.02 | -0.01 | - | - |
| Free Cash Flow | -7.75 | -6.87 | -2.18 | -1.25 | -0.69 |
| Cash & Equivalents | 2.00 | 8.60 | 0.16 | 1.60 | 0.24 |
| Net Cash / Debt | 2.00 | 8.60 | 0.16 | 1.60 | 0.24 |
| Assets | 3.53 | 9.27 | 1.26 | 1.91 | 0.41 |
| Liabilities | 0.51 | 0.39 | 0.83 | 0.29 | 0.02 |
| Book Value | 3.02 | 8.88 | 0.43 | 1.62 | 0.39 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Genprex, Inc. |
| Country |
United States |
| Employees |
8 |
| CEO |
J. Rodney Varner |
Stock Information
| Ticker Symbol |
GNPX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GNPX |
| IPO Date |
March 29, 2018 |
Description
Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company's lead product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex also block mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.